ES2275881T3 - Uso de un alcanoil l-carnitina para la preparacion de una medicacion para tratar anhedonia. - Google Patents

Uso de un alcanoil l-carnitina para la preparacion de una medicacion para tratar anhedonia. Download PDF

Info

Publication number
ES2275881T3
ES2275881T3 ES02741156T ES02741156T ES2275881T3 ES 2275881 T3 ES2275881 T3 ES 2275881T3 ES 02741156 T ES02741156 T ES 02741156T ES 02741156 T ES02741156 T ES 02741156T ES 2275881 T3 ES2275881 T3 ES 2275881T3
Authority
ES
Spain
Prior art keywords
stress
carnitine
acetyl
rats
exposed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02741156T
Other languages
English (en)
Spanish (es)
Inventor
Menotti Sigma-Tau Ind. Farm. Riunite SpA CALVANI
Luigi Sigma-Tau Ind. Farm. Riunite SpA MOSCONI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT2001RM000292A external-priority patent/ITRM20010292A1/it
Priority claimed from IT2001RM000319A external-priority patent/ITRM20010319A1/it
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Application granted granted Critical
Publication of ES2275881T3 publication Critical patent/ES2275881T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES02741156T 2001-05-29 2002-05-24 Uso de un alcanoil l-carnitina para la preparacion de una medicacion para tratar anhedonia. Expired - Lifetime ES2275881T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT2001RM000292A ITRM20010292A1 (it) 2001-05-29 2001-05-29 Uso dell'acetil l-carnitina per la preparazione di un medicamento peril trattamento dell'anedonia.
ITRM01A0029 2001-05-29
ITRM01A0031 2001-06-07
IT2001RM000319A ITRM20010319A1 (it) 2001-06-08 2001-06-08 Uso di una alcanoil l-carnitina per la preparazione di un medicamentoper il trattamento dell'anedonia.

Publications (1)

Publication Number Publication Date
ES2275881T3 true ES2275881T3 (es) 2007-06-16

Family

ID=26332845

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02741156T Expired - Lifetime ES2275881T3 (es) 2001-05-29 2002-05-24 Uso de un alcanoil l-carnitina para la preparacion de una medicacion para tratar anhedonia.

Country Status (16)

Country Link
US (2) US20040171685A1 (https=)
EP (1) EP1399143B1 (https=)
JP (1) JP2004532867A (https=)
KR (1) KR20040003031A (https=)
AT (1) ATE345124T1 (https=)
CA (1) CA2448246A1 (https=)
CZ (1) CZ20033222A3 (https=)
DE (1) DE60216090T2 (https=)
DK (1) DK1399143T3 (https=)
ES (1) ES2275881T3 (https=)
HU (1) HUP0400007A2 (https=)
MX (1) MXPA03010920A (https=)
PL (1) PL367628A1 (https=)
PT (1) PT1399143E (https=)
SK (1) SK15862003A3 (https=)
WO (1) WO2002096411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
CA3238205A1 (en) 2021-11-12 2023-05-19 Rajaram Samant A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1291930B1 (it) * 1997-06-18 1999-01-21 Sigma Tau Ind Farmaceuti Composizione riequilibratrice delle turbe dell'umore in individui sani

Also Published As

Publication number Publication date
CZ20033222A3 (cs) 2004-06-16
ATE345124T1 (de) 2006-12-15
CA2448246A1 (en) 2002-12-05
US20060148896A1 (en) 2006-07-06
DE60216090D1 (de) 2006-12-28
DK1399143T3 (da) 2007-03-26
WO2002096411A1 (en) 2002-12-05
KR20040003031A (ko) 2004-01-07
PL367628A1 (en) 2005-03-07
EP1399143A1 (en) 2004-03-24
HUP0400007A2 (hu) 2004-04-28
SK15862003A3 (sk) 2004-06-08
US20040171685A1 (en) 2004-09-02
DE60216090T2 (de) 2007-05-31
EP1399143B1 (en) 2006-11-15
MXPA03010920A (es) 2004-02-27
JP2004532867A (ja) 2004-10-28
PT1399143E (pt) 2007-01-31

Similar Documents

Publication Publication Date Title
ES2500053T3 (es) Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
ES2380510T3 (es) Nuevo uso de compuestos peptídicos para tratar discinesia
ES2450615T3 (es) Composiciones que comprenden Tramadol y Celecoxib para el tratamiento del dolor
JP5085541B2 (ja) 疲労軽減剤
ES2300141T3 (es) Asociaciones de riluzol y levodopa para el tratamiento de la enfrmedad de parkinson.
WO1998057629A1 (en) Composition for controlling mood disorders in healthy individuals
ES3057870T3 (en) Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
ES2281545T3 (es) Uso de derivados de 2-oxo-1-pirrolidina para la preparacion de un farmaco para tratar la discinesia.
ES2940822T3 (es) Agente elevador de la concentración de óxido nítrico
ES2906614T3 (es) Agente para evitar o mejorar el deterioro de la función cerebral
ES2244070T3 (es) Uso de analogos de gaba, tal como gabapentina, en la fabricacion de un medicamento para tratar enfermedades inflamatorias.
ES2275881T3 (es) Uso de un alcanoil l-carnitina para la preparacion de una medicacion para tratar anhedonia.
HUP0004336A2 (hu) Készítmény alkoholistákban fellépő megvonási tünetek és alkohol iránti ellenállhatatlan szükségérzet elnyomására és az alkohol túlzott mértékű fogyasztásának megelőzésére egészséges alanyokban
ES2312657T3 (es) Utilizacion de desoxipeganina en el tratamiento de la depresion clinica.
ES2992560T3 (es) Preparación farmacéutica o de suplemento alimenticio basada en alfa-lactoalbúmina
CN103181928B (zh) 水杨酸甲酯糖苷在预防和/或治疗阿尔茨海默病的应用
ES3038949T3 (en) Compounds for use in the treatment of attention deficit hyperactivity disorder
BR112021015682A2 (pt) Combinação de silício e magnésio para a prevenção e tratamento contra cãibras musculares
MUKASA et al. A new double medication method for the treatment of alcoholism using the drug cyanamide
ES2205516T3 (es) Uso de 1-ar(alqu)il-imidazolin-2-onas para tratar estados de ansiedad y de tension.
ES2211334B1 (es) Suplemento nutricional para el tratamiento de sindromes relacionados con la fatiga.
ES2326355B1 (es) Acido 1-(di-n-propilacetilaminometil)-ciclohexilacetico.
ES3034261T3 (en) Amiselimod for use in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome
WO2011088536A1 (pt) Uso de pelo menos um composto isoquinolínico de fórmula i, composição farmacêutica para tratar ou prevenir doenças neurodegenerativas e método para tratamento ou prevenção de doenças neurodegenerativas
BR112019026660B1 (pt) Uso de acetil-leucina ou seu sal para preparação demedicamento para tratar ou prevenir enxaqueca ou sintomas associados